Dassault Systèmes and CDR-Life Collaborate to Accelerate Scientific Innovation for Cancer Therapies

2024-03-12

免疫疗法

Dassault Systèmes, a science-based leader in virtual twin experiences and CDR-Life, a Swiss biotherapeutics company, partnered to study the stability of antibody-based biologics Dassault Systèmes’ Contract Research team used BIOVIA software to run virtual “what if” experiments that identified stabilizing variants VELIZY-VILLACOUBLAY, France--(BUSINESS WIRE)-- Dassault Systèmes (Euronext Paris: FR0014003TT8, DSY.PA) today announced it collaborated with CDR-Life, a Swiss biotherapeutics company, to accelerate CDR-Life’s development of next-generation highly tumor-selective immunotherapies using CDR-Life’s proprietary M-gager® platform. Scientists from Dassault Systèmes’ Contract Research team worked closely with scientists from CDR-Life to perform virtual “what if” experiments on antibody-based biologics called T-cell engagers, using Dassault Systèmes’ BIOVIA software and CDR-Life’s experimental data. Dassault Systèmes’ Contract Research team leveraged its expertise in science and technology to model different molecules virtually, and identify ones that will have desirable properties such as stability, without impacting other molecular function. Following a holistic and systematic analysis of the results, the team provided the variants that were anticipated to have a high probability of success when tested in the lab by CDR-Life. “Our collaboration with Dassault Systèmes’ Contract Research team accelerated our research and development efforts based on our proprietary antibody-based MHC-targeting T-cell engager technology. By working together, we can use the insights gathered virtually for our protein engineering platform and pave the way toward more efficient and effective oncology treatments,” said Fabian Scheifele, Discovery Leader, CDR-Life. Next generation immunotherapies are a key step in the successful treatment of cancer, as they empower the immune system to eradicate malignant cells with unparalleled specificity. Improving the stability of antibody-based T-cell engagers can result in high tumor cell killing potency, longer duration of effect, and lower risk of immune-related adverse effects. “The complexity of unmet medical needs affects the patient experience and health outcomes. Pharmaceutical and biotechnology companies of all sizes seek to accelerate the development of therapies that will help people live healthier lives,” said Claire Biot, Vice President, Life Sciences & Healthcare Industry, Dassault Systèmes. “Our outcome-based Contract Research service is a game-changer in how we work with our customers on projects. CDR-Life was able to focus its time and energy on prioritized experiments with the most promising candidates. Not only did this narrow down the number of experiments its scientists needed to perform in their lab, it provided new insights that helped them reach their end-goals faster.” As a science-based company, Dassault Systèmes, through its Contract Research team, provides solutions to business-critical scientific challenges that its existing and new customers in all industries face. During the pandemic, for example, these services delivered actionable results and insights for projects to model, simulate and evaluate virus propagation risks in hospitals, offices and public spaces. ### FOR MORE INFORMATION Dassault Systèmes’ 3DEXPERIENCE platform, 3D design software, 3D Digital Mock Up and Product Lifecycle Management (PLM) solutions: M-gager is a proprietary technology and registered trademark of CDR-Life. SHARE THIS ON X, FORMERLY KNOWN AS TWITTER New collaboration between @Dassault3DS and CDR-Life to accelerate scientific innovation for cancer therapies #3DEXPERIENCE Connect with Dassault Systèmes on ABOUT DASSAULT SYSTÈMES Dassault Systèmes, the 3DEXPERIENCE® Company, is a catalyst for human progress. We provide business and people with collaborative virtual environments to imagine sustainable innovations. By creating virtual twin experiences of the real world with our 3DEXPERIENCE platform and applications, our customers can redefine the creation, production and life-cycle-management processes of their offer and thus have a meaningful impact to make the world more sustainable. The beauty of the Experience Economy is that it is a human-centered economy for the benefit of all –consumers, patients and citizens. Dassault Systèmes brings value to more than 300,000 customers of all sizes, in all industries, in more than 150 countries. For more information, visit © Dassault Systèmes. All rights reserved. 3DEXPERIENCE, the 3DS logo, the Compass icon, IFWE, 3DEXCITE, 3DVIA, BIOVIA, CATIA, CENTRIC PLM, DELMIA, ENOVIA, GEOVIA, MEDIDATA, NETVIBES, OUTSCALE, SIMULIA and SOLIDWORKS are commercial trademarks or registered trademarks of Dassault Systèmes, a European company (Societas Europaea) incorporated under French law, and registered with the Versailles trade and companies registry under number 322 306 440, or its subsidiaries in the United States and/or other countries. View source version on businesswire.com: Contacts Dassault Systèmes Press Contacts Corporate / France Arnaud MALHERBE arnaud.malherbe@3ds.com +33 (0)1 61 62 87 73 North America Natasha LEVANTI natasha.levanti@3ds.com +1 (508) 449 8097 EMEA Virginie BLINDENBERG virginie.blindenberg@3ds.com +33 (0) 1 61 62 84 21 China Grace MU grace.mu@3ds.com +86 10 6536 2288 India Kriti ASHOK kriti.ashok@3ds.com +91 9741310607 Japan Wen YANG wen.yang@3ds.com +81 3 4321 6549 Korea Jeemin JEONG jeemin.jeong@3ds.com +82 2 3271 6653 Source: Dassault Systèmes View this news release online at: